[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336669-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336669-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tissue-factor-pathway-inhibitor-2-as-a-serum-biomarker-for-endometrial-cancer-a-single-center-retrospective-study","Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer - a single-center retrospective study","","Endometrial cancer is the most common gynecological malignancy, yet clinically useful blood-based diagnostic biomarkers remain lacking. This single-center retrospective study evaluated serum tissue factor pathway inhibitor 2 (TFPI2) as a diagnostic marker for endometrial cancer, comparing 328 patients with endometrial cancer to 65 healthy controls. Serum TFPI2 showed diagnostic performance, association with stage and high-risk histology, and prognostic impact, while tissue and serum TFPI2 positivity showed no meaningful correlation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tissue-factor-pathway-inhibitor-2-as-a-serum-biomarker-for-endometrial-cancer-a-single-center-retrospective-study/336669/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tissue-factor-pathway-inhibitor-2-as-a-serum-biomarker-for-endometrial-cancer-a-single-center-retrospective-study/336669.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study on TFPI2?","Question",{"text":63,"@type":64},"To determine whether serum tissue factor pathway inhibitor 2 (TFPI2) can serve as a diagnostic marker for endometrial cancer and to assess related clinicopathological associations and prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did serum TFPI2 levels differ between patients and healthy controls?",{"text":68,"@type":64},"Patients with endometrial cancer had significantly higher serum TFPI2 levels than healthy controls (196.7 pg/mL vs. 83.3 pg/mL, p \u003C 0.001).",{"name":70,"@type":61,"acceptedAnswer":71},"Was there a relationship between serum TFPI2 and tissue TFPI2 positivity?",{"text":72,"@type":64},"No correlation was found between serum TFPI2 levels and TFPI2 immunostaining scores in tumor tissues, with poor agreement reported between serum and tissue results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336669,1790144067,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Uomoto etal. BMC Cancer (2024) 24:1058 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12827-0](https://doi.org/10.1186/s12885-024-12827-0)  \nRESEARCH Open Access  \nTissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-  \ncenter retrospective study  \nMari Uomoto 1,2,3†, Yukihide Ota 1,2,4†, Yukio Suzuki2,3, Asuna Yumori3, Hiroto Narimatsu5, Shiro Koizume 1, Shinya Sato 1,6, Yoshiyasu Nakamura 1, Shohei Myoba7, Norihisa Ohtake7, Haruya Saji3, Etsuko Miyagi2 and Yohei Miyagi 1,6*  \nAbstract  \nBackground Endometrial cancer is the most common gynecological malignancy; however, there is no useful blood diagnostic biomarker. This study aimed to determine the utility of tissue factor pathway inhibitor 2 (TFPI2), abiomarker of ovarian cancer, as a diagnostic marker for endometrial cancer.  \nMethods We examined serum TFPI2 levels in patients with endometrial cancer (n = 328) compared to those in healthy controls (n = 65) and evaluated the performance of serumTFPI2 levels as a diagnostic marker. We investigated the clinicopathological characteristics of patients with TFPI2-negative and TFPI2-positive endometrial cancer. Using immunohistochemistry (IHC), we examined TFPI2 expression in tumor tissues of 105 patients with type II endometrial carcinoma and evaluated the correlation between serum and tissue TFPI2 positivity.  \nResults Patients with endometrial cancer had significantly higher serum TFPI2 levels than controls (196 .7 pg/mL vs. 83.3 pg/mL; p \u003C 0. 001) . The sensitivity and specificity were 54 . 3% and 95 .4%, respectively (cutoff value, 191 pg/ mL) . Serum TFPI2 levels were significantly elevated along with the stage progression (stage I, 189.6 pg/mL; stage III, 230.9 pg/mL; stage IV, 312.5 pg/mL; p \u003C 0. 001) . Patients with high-risk histology showed significantly elevated serum TFPI2 levels than those with low-risk histology (220 . 8 pg/mL vs. 187.7 pg/mL; p \u003C 0. 001) . The positivity rate forTFPI2 was the highest among tumor markers, including CA125, CA19-9, and CEA. Serum TFPI2 and CA125 levels were almost independent (r = 0 . 203, p \u003C 0. 001), and the combined sensitivity increased to 58 . 8% . The 5-year survival rate was significantly worse inTFPI2-positive patients (≥ 191 pg/mL, n = 178) than inTFPI2-negative patients (\u003C 191 pg/ mL, n = 150) (hazard ratio, 8 . 22; 95% confidence interval, 2 .49–27. 1; p \u003C 0. 001) . TFPI2 immunostaining revealed that 37. 1%(39/105) of the samples were positive forTFPI2, with an IHC score of > 0. There was no significant difference in the immunostaining score according to histological type. Serum TFPI2 levels and immunostaining score showed poor agreement (kappa coefficient, -0 . 039) .  \n†Mari Uomoto and Yukihide Ota share the first authorship.  \n*Correspondence:  \nYohei Miyagi [miyagi.0e82r@kanagawa-pho.jp](miyagi.0e82r@kanagawa-pho.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommon","cbCaikOaJv2fQyC3","https://ap.wps.com/l/cbCaikOaJv2fQyC3","pdf",2109414,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background","[{\"question\":\"What was the main goal of this study on TFPI2?\",\"answer\":\"To determine whether serum tissue factor pathway inhibitor 2 (TFPI2) can serve as a diagnostic marker for endometrial cancer and to assess related clinicopathological associations and prognosis.\"},{\"question\":\"How did serum TFPI2 levels differ between patients and healthy controls?\",\"answer\":\"Patients with endometrial cancer had significantly higher serum TFPI2 levels than healthy controls (196.7 pg/mL vs. 83.3 pg/mL, p \\u003c 0.001).\"},{\"question\":\"Was there a relationship between serum TFPI2 and tissue TFPI2 positivity?\",\"answer\":\"No correlation was found between serum TFPI2 levels and TFPI2 immunostaining scores in tumor tissues, with poor agreement reported between serum and tissue results.\"}]","Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer - a single-center retrospective study | PDF",1790016114,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21801eb69951469c9faea43e5df9ee5d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f56266e9cc6f2faf970acfc5451b086.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d91504f72c33e8116bffb84edf9dedde.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba5266710f67c923b6ca1b800397284a.webp",980,1306]